Exeliom Biosciences
1 known investors
Exelion Bio develops EXL01, a first-in-class innate immune conditioner that reprograms myeloid cells to restore anti-tumor immunity for use in combination with checkpoint inhibitors for cancer treatment. The company targets immuno-oncology and other immunological disorders through a proprietary vaccine-like manufacturing process.
BiotechDeep TechMedical Devices